Appendix B: General Terms

Actualizado 27/06/2024 - 12:00 Reviewed Jue, 27/06/2024 - 12:00

Appendix B: Acronyms

General Terms
Acronym	Term
°C	degrees Celsius
°F	degrees Fahrenheit
% v	volume
25-OH-vitamin D	25-hydroxy vitamin D
AAP	American Academy of Pediatrics
ACTH	adrenocorticotropic hormone
AE	adverse effect
AHR	adjusted hazard ratio
ALT	alanine aminotransferase
ANC	absolute neutrophil count
app	mobile application
ART	antiretroviral therapy
ARV	antiretroviral
ASCVD	atherosclerotic cardiovascular disease
AST	aspartate aminotransferase
AUC	area under the curve
AUC_0-12h	area under the curve from 0 to 12 hours postdose
AUC_12h	12-hour area under the curve
AUC_24h	24-hour area under the curve
AUC_tau	area under the curve over the dosing interval
AV	atrioventricular
BCRP	breast cancer resistance protein
BHIVA	British HIV Association
BMD	bone mineral density
BMI	body mass index
BSA	body surface area
C_0h	pre-dose concentration
C_12h	concentration at 12 hours
C24h	concentration at 24 hours
CAR	chimeric antigen receptor
C_avg	average plasma concentration
CBC	complete blood count
CD4	CD4 T lymphocyte
CD8	CD8 T lymphocyte
CDC	Centers for Disease Control and Prevention
CEPAC	Cost-Effectiveness of Preventing AIDS Complications, a model
CI	confidence interval
CK	creatine kinase
C_max	maximum plasma concentration
C_min	minimum plasma concentration
CMV	cytomegalovirus
CNS	central nervous system
COMB-R	cognitive behavioral therapy and medication management algorithm
Cr	creatinine
CRAFFT	Car, Relax, Alone, Forget, Friends, and Trouble
CrCl	creatinine clearance
CT	continuous therapy
C_tau	concentration at the end of a dosing interval
Ct_rough	trough concentration
CT_x	C-telopeptide of type 1 collagen
CV	coefficients of variation
CVD	cardiovascular disease
CYP	cytochrome P450
CYPB26	cytochrome P450 family 2 subfamily B member 6
DAIDS	Division of AIDS (NIAID)
DBS	dried blood spot
DM	diabetes mellitus
DOT	directly observed therapy
DRESS	drug reaction (or rash) with eosinophilia and systemic symptoms
DSG	delayed switch group
DT	dispersible tablet
DXA	dual energy x-ray absorptiometry
EBV	Epstein-Barr virus
EC	enteric-coated
EC₅₀	half maximal effective concentration
ECG	electrocardiogram
ECMO	extracorporeal membrane oxygenation
EEG	electroencephalogram
eGFR	estimated glomerular filtration rate
EM	erythema multiforme or extensive metabolizers
FCT	film-coated tablet
FDA	U.S. Food and Drug Administration
FDC	fixed-dose combination
FLP	fasting lipid profile
FPG	fasting plasma glucose
g/dL	grams per deciliter
G6PD	glucose-6-phosphate dehydrogenase
GA	gestational age
GFR	glomerular filtration rate
GI	gastrointestinal
GLSM	geometric least squares mean
GM	geometric mean
GMR	geometric mean ratio
gp120	glycoprotein 120
HA	height age
HAV	hepatitis A virus
HBcAB	HBV core antibody
HBsAB	HBV surface antibody
HBsAG	HBV surface antigen
HBV	hepatitis B virus
HCV	hepatitis C virus
HD	high dose
HDL	high-density lipoprotein
HDL-C	high-density lipoprotein cholesterol
Hgb	hemoglobin
HgbA1c	glycosylated hemoglobin
HHS	U.S. Department of Health and Human Services
HIV RNA or HIV-1 RNA	viral load
HLA	human leukocyte antigen
HMG-CoA	3-hydroxy-3-methylglutaryl coenzyme A
HRSA	Health Resources and Services Administration
HSR	hypersensitivity reaction
HSV	herpes simplex virus
IAS-USA	International Antiviral Society-USA
IFPG	impaired fasting plasma glucose
IGT	impaired glucose tolerance
IM	intramuscular
INSTI	integrase strand transfer inhibitor
IQ	inhibitory quotient
IQR	interquartile range
IR	insulin resistance
IRIS	immune reconstitution inflammatory syndrome
ISG	immediate switch group
IU	international units
IV	intravenous
IVIG	intravenous immune globulin
L	liter
LAI	long-acting injectable
LBW	low birth weight
LDL	low-density lipoprotein
LDL-C	low-density lipoprotein cholesterol
LFT	liver function test
Log₁₀	the logarithm to the base 10
LS	lipodystrophy syndrome
LVH	left ventricular hypertrophy
MCV	mean cell volume
mDAART	modified directly administered ART
MEMS	medication event monitoring system
N/A	not available or not applicable
NASBA	nucleic acid sequence-based amplification
NAT	nucleic acid test
NHLBI	National Heart, Lung, and Blood Institute
NIH	National Institutes of Health
nM	nanometer
NNRTI	non-nucleoside reverse transcriptase inhibitor
NRTI	nucleoside reverse transcriptase inhibitor
NTD	neural tube defect
OARAC	Office of AIDS Research Advisory Council
OAT	organic anion transporter
OATP	organic anion transporter polypeptide
OBT	optimized background therapy
OGTT	oral glucose tolerance test
OI	opportunistic infection
OR	odds ratio
PA-IC₉₅	protein-adjusted IC₉₅
The Panel	the Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV
PBMC	peripheral blood mononuclear cell
PCP	Pneumocystis jirovecii pneumonia
PEPFAR	President's Emergency Plan for AIDS relief
PCR	polymerase chain reaction
PEP	post-exposure prophylaxis
PG	plasma glucose
P-gp	P-glycoprotein
PHIV	perinatally acquired HIV
PK	pharmacokinetic
PI	protease inhibitor
POC	point of care
PPI	proton pump inhibitor
PrEP	pre-exposure prophylaxis
py	patient years
QTc	corrected QT
RCT	randomized controlled trial
RPG	random plasma glucose
RR	relative risk
RT-PCR	reverse transcription polymerase chain reaction
SAM	severe acute malnutrition
SBIRT	Screening, Brief, Intervention, and Referral to Treatment
SCT	short-cycle therapy
SD	standard deviation
SJS	Stevens-Johnson syndrome
SM	slow metabolizers
SMR	sexual maturity rating
SMS	short message service
SOC	standard of care
SQ	subcutaneous
STI	sexually transmitted infection
STR	single-tablet regimen
T_½	half-life
TB	tuberculosis
TBLH	total body less head
TC	total cholesterol
TDM	therapeutic drug monitoring
TEN	toxic epidermal necrolysis
TG	triglyceride
TIC	trauma-informed care
TMA	transcription-mediated amplification
T_max	time to reach maximum concentration
U=U	Undetectable = Untransmittable
UGT	uridine diphosphate glucuronosyltransferase
UGT1A and UGT1A1	uridine diphosphate (UDP)-glucuronosyltransferase family 1 member A complex or uridine diphosphate (UDP)-glucuronosyltransferase family 1 member A complex 1
ULN	upper limit of normal
v/v	volume per volume
w	weight
WHO	World Health Organization

Appendix B: Acronyms

General Terms
Acronym	Term
°C	degrees Celsius
°F	degrees Fahrenheit
% v	volume
25-OH-vitamin D	25-hydroxy vitamin D
AE	adverse effect
AHR	adjusted hazard ratio
ALT	alanine aminotransferase
ANC	absolute neutrophil count
app	mobile application
ART	antiretroviral therapy
ARV	antiretroviral
ASCVD	atherosclerotic cardiovascular disease
AST	aspartate aminotransferase
AUC	area under the curve
AUC_0-12h	area under the curve at 12 hours post-dose
AUC_24h	area under the curve at 24 hours post-dose
AUC_tau	area under the curve
AV	atrioventricular
BCRP	breast cancer resistance protein
BHIVA	British HIV Association
BMD	bone mineral density
BMI	body mass index
BSA	body surface area
C_0h	pre-dose concentration
C_12h	concentration at 12 hours
C24h	concentration at 24 hours
CAR	chimeric antigen receptor
C_avg	average plasma concentration
CBC	complete blood count
CD4	CD4 T lymphocyte
CDC	Centers for Disease Control and Prevention
CI	confidence interval
CK	creatine kinase
C_max	maximum plasma concentration
C_min	minimum plasma concentration
CMV	cytomegalovirus
CNS	central nervous system
Cr	creatinine
CrCl	creatinine clearance
CT	continuous therapy
C_tau	concentration at the end of a dosing interval
Ct_rough	trough concentration
CT_x	C-telopeptide of type 1 collagen
CV	coefficients of variation
CVDI	cardiovascular disease
CYP	cytochrome P
CYPB26	cytochrome P450 family 2 subfamily B member 6
DAIDS	Division of AIDS (NIAID)
DBS	dried blood spot
dL	deciliter
DM	diabetes mellitus
DNA	deoxyribonucleic acid
DOT	directly observed therapy
DRESS	drug reaction (or rash) with eosinophilia and systemic symptoms
DSG	delayed switch group
DSMB	Data Safety Monitoring Board
DT	dispersible tablet
DXA	dual energy x-ray absorptiometry
E2D2	Every Dose, Every Day [Toolkit and App]
EBV	Epstein-Barr virus
EC	enteric-coated
EC₅₀	half maximal effective concentration
ECG	electrocardiogram
EEG	electroencephalogram
eGFR	estimated glomerular filtration rate
EM	erythema multiforme or extensive metabolizers
FCT	film-coated tablet
FDA	Food and Drug Administration
FDC	fixed-dose combination
fL	femtoliter
FLP	fasting lipid profile
fmol	femtomole
FPG	fasting plasma glucose
g	gram
g/dL	grams per deciliter
G6PD	glucose-6-phosphate dehydrogenase
GA	gestational age
GFR	glomerular filtration rate
GI	gastrointestinal
GLSM	geometric least squares mean
GM	geometric mean
GMR	geometric mean ratio
gp	glycoprotein
gp120	glycoprotein 120
h	hour
HA	height age
HAV	hepatitis A virus
HBV	hepatitis B virus
HCV	hepatitis C virus
HD	high dose
HDL-C	high-density lipoprotein cholesterol
Hgb	hemoglobin
HgbA1c	glycosylated hemoglobin
HHS	Department of Health and Human Services
HIV RNA or HIV-1 RNA	viral load
HLA	human leukocyte antigen
HRSA	Health Resources and Services Administration
HSR	hypersensitivity reaction
HSV	herpes simplex virus
IAS-USA	International Antiviral Society-USA
IFPG	impaired fasting plasma glucose
IGT	impaired glucose tolerance
IM	intramuscular
INSTI	integrase strand transfer inhibitor
IQ	inhibitory quotient
IQR	interquartile range
IR	insulin resistance
IRIS	immune reconstitution inflammatory syndrome
ISG	immediate switch group
IU	international units
IV	intravenous
IVIG	intravenous immune globulin
kg	kilogram
L	liter
LAI	long-acting injectable
LBW	low birth weight
LDL	low-density lipoprotein
LDL-C	low-density lipoprotein cholesterol
LFT	liver function test
Log₁₀	the logarithm to the base 10
LS	lipodystrophy syndrome
LVH	left ventricular hypertrophy
m²	square meter
mcg	microgram
MCV	mean cell volume
mDAART	modified directly administered ART
MEMS	Medication Event Monitoring System
mg	milligram
min	minute
mL	milliliter
mm	millimeter
mm³	cubic millimeter
mmol	millimole
N/A	not available or not applicable
NASBA	nucleic acid sequence-based amplification
NAT	nucleic acid test
ng	nanogram
NHLBI	National Heart, Lung, and Blood Institute
NIH	National Institutes of Health
nM	nanometer
NNRTI	non-nucleoside reverse transcriptase inhibitor
NRTI	nucleoside reverse transcriptase inhibitor
NTD	neural tube defect
OARAC	Office of AIDS Research Advisory Council
OAT	organic anion transporter
OATP	organic anion transporter polypeptide
OBT	optimized background therapy
OGTT	oral glucose tolerance test
OI	opportunistic infection
oz	ounce
PA-IC₉₅	protein-adjusted IC₉₅
The Panel	the Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV
PBMC	peripheral blood mononuclear cell
PCP	Pneumocystis jirovecii pneumonia
PCR	polymerase chain reaction
PEP	post-exposure prophylaxis
PG	plasma glucose
P-gp	P-glycoprotein
PI	protease inhibitor
PK	pharmacokinetic
POC	point of care
PPI	proton pump inhibitor
PrEP	pre-exposure prophylaxis
PUFA	polyunsaturated fatty acid
py	patient years
QTc	corrected QT
RCT	randomized controlled trial
RNA	ribonucleic acid
RPG	random plasma glucose
RR	relative risk
RT-PCR	reverse transcription polymerase chain reaction
SAM	severe acute malnutrition
SCT	short-cycle therapy
SD	standard deviation
SJS	Stevens-Johnson syndrome
SM	slow metabolizers
SMR	sexual maturity rating
SMS	short message service
SOC	standard of care
SQ	subcutaneous
STI	sexually transmitted infection
STR	single-tablet regimen
T_½	half-life
TB	tuberculosis
TBLH	total body less head
TC	total cholesterol
TDM	therapeutic drug monitoring
TEN	toxic epidermal necrolysis
TG	triglyceride
TMA	transcription-mediated amplification
T_max	time to reach maximum concentration
U=U	Undetectable = Untransmittable
UGT	uridine diphosphate glucuronosyltransferase
UGT1A	uridine diphosphate (UDP)-glucuronosyltransferase family 1 member A complex
ULN	upper limit of normal
v/v	volume per volume
w	weight
WHO	World Health Organization
XR	extended release

Download Guidelines

Section Only PDF (79.15 KB)
Full Guideline PDF (5.98 MB)
Recommendations Only PDF (706.95 KB)
Tables Only PDF (1.03 MB)
Drug Tables Only PDF (2.38 MB)

Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Appendix B: Acronyms

Appendix B: Acronyms

Download Guidelines

Related Content